Sector revisions Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Equities

End-of-day quote Shanghai S.E. Other stock markets 2026-01-16			5-day change	1st Jan Change
61.94 ^CNY	-1.95%		-2.88%	+3.98%

Jan. 12	Hengrui Pharma Unit Secures Approval to Conduct Clinical Trial for Hypertension Drug	MT
Jan. 12	Hengrui Pharma's Cancer Drug Obtains China Breakthrough Therapy Designation	MT

Sector:

Location:

X axis:

Main competitors

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	4m. EPS revision	4m. Revenue rev.	1y. EPS revision	1y. Revenue rev.	Visibility	Nbr of analysts
	JIANGSU HENGRUI PHARMACEUTICALS CO.,LTD							17
	ELI LILLY AND COMPANY							28
	JOHNSON & JOHNSON							24
	ABBVIE INC.							27
	ROCHE HOLDING AG							19
	ASTRAZENECA PLC							20
	NOVARTIS AG							20
	MERCK & CO., INC.							27
	NOVO NORDISK A/S							21
	AMGEN INC.							27
	GILEAD SCIENCES, INC.							26
	PFIZER INC.							24
	SANOFI							22
	BRISTOL-MYERS SQUIBB COMPANY							23
	VERTEX PHARMACEUTICALS INCORPORATED							25
	GSK PLC							19
	CHUGAI PHARMACEUTICAL CO., LTD.							14
	TAKEDA PHARMACEUTICAL COMPANY LIMITED							15
	ALNYLAM PHARMACEUTICALS, INC.							25
	Average							22
	Weighted average by Cap.							24